Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.

被引：0

作者：

Carril-Ajuria, Lucia

Naigeon, Marie

Dalban, Cecile

Desnoyer, Aude

Rioux-Leclercq, Nathalie

Sautes-Fridman, Catherine

Meylan, Maxime

Vano, Yann-Alexandre

Beusenlick, Benoit

Chouaib, Salem

de Oliveira, Caroline

Tantot, Florence

Flippot, Ronan

Escudier, Bernard

Albiges, Laurence

Chaput, Nathalie

机构：

[1] Inst Gustave Roussy, Med Oncol, Villejuif, France

[2] Gustave Roussy, Lab Immunomonitoring Oncol, Villejuif, France

[3] Ctr Leon Berard, Lyon, France

[4] AP HP, Paris, France

[5] Pontchaillou Univ Hosp Ctr, Rennes, France

[6] Sorbonne Univ, Univ Paris Cite, INSERM, Ctr Rech Cordeliers, Paris, France

[7] Univ Paris Cite, Dept Med Oncol, Hop Europeen Georges Pompidou, AP HP Ctr,Inst Canc Paris CARPEM,, Paris, France

[8] Univ Hosp Leuven, Gen Med Oncol, B-3000 Leuven, Belgium

[9] Gustave Roussy Canc Campus, Villejuif, France

[10] Gustave Roussy, Lab Immunooncol, F-94800 Villejuif, France

[11] UNICANCER, Le Kremlin Bicetre, France

[12] Gustave Roussy, Villejuif, MA, France

[13] Univ Paris Sud, Dept Canc Med, Gustave Roussy Canc Campus, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

724

引用

页数：1

共 50 条

[41] Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
Rotllan, N. Baste
Auperin, A.
Iacob, M.
Sampetrean, A.
Bouguetta, D.
Badis, L. Mayache
Ferrand, F. R.
Casiraghi, O.
Blanchard, P.
Bidault, F.
Gorphe, P.
Temam, S.
Champiat, S.
Even, C.
Marabelle, A.
ANNALS OF ONCOLOGY, 2019, 30 : 470 - 470
[42] Risk Factors of Immune Related Adverse Events in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Chehade, Razane El Hajj
Semaan, Karl
Saliby, Renee Maria
Saad, Eddy
Nawfal, Rashad
Machaalani, Marc
Eid, Marc
Yekeduz, Emre
Steiner, Clara
Sun, Maxine
Kaymakcalan, Marina
Choueiri, Toni K.
ONCOLOGIST, 2024, 29
[43] Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Pavan, A.
Calvetti, L.
Dal Maso, A.
Fabozzi, A.
Piccin, L.
Chiarion-Sileni, V.
Pasello, G.
Aprile, G.
Guarneri, V.
Conte, P. F.
Bonanno, L.
ANNALS OF ONCOLOGY, 2019, 30 : 45 - 45
[44] Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study
Vitale, M. G.
Pipitone, S.
Scagliarini, S.
Zucali, P. A.
Galli, L.
Rossetti, S.
Caserta, C.
Iacovelli, R.
Masini, C.
Ficorella, C.
Di Girolamo, S.
Buti, S.
Benedetti, B.
Santoni, M.
Porta, C.
Bracarda, S.
Baldessari, C.
Giaquinta, S.
Cascinu, S.
Sabbatini, R.
ANNALS OF ONCOLOGY, 2018, 29
[45] Outcomes in PD-1/PD-L1 responders who discontinued therapy for immune-related adverse events (irAEs): analysis of nine patients with metastatic renal cell carcinoma (mRCC)
Martini, Dylan
Brandao, Raphael
Hamieh, Lana
Norton, Craig
Mullane, Stephanie
Walsh, Meghara
Van Allen, Eliezer
Mckay, Rana
Harshman, Lauren
Choueiri, Toni
BJU INTERNATIONAL, 2016, 118 : 10 - 11
[46] Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial
Colomba, E.
Ajuria, L. Carril
Dalban, C.
Derosa, L.
Silva, C. Alves Costa
Rassy, E.
Negrier, S.
Chevreau, C. M.
Mescam, G. Gravis
Oudard, S.
Laguerre, B.
Barthelemy, P.
Goupil, M. Gross
Geoffrois, L.
Thiery-Vuillemin, A.
Lobbedez, F. Joly
Ladoire, S.
Tantot, F.
Escudier, B.
Albiges, L.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1223 - S1224
[47] Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study
Nukaya, Takuhisa
Takahara, Kiyoshi
Yoshizawa, Atsuhiko
Saruta, Masanobu
Yano, Yusuke
Ohno, Takaya
Uchimoto, Taizo
Fukuokaya, Wataru
Adachi, Takahiro
Yamazaki, Shogo
Tokushige, Satoshi
Nishimura, Kazuki
Tsujino, Takuya
Nakamori, Keita
Yamamoto, Shutaro
Iwatani, Kosuke
Urabe, Fumihiko
Mori, Keiichiro
Yanagisawa, Takafumi
Tsuduki, Shunsuke
Hirasawa, Yosuke
Hashimoto, Takeshi
Komura, Kazumasa
Inamoto, Teruo
Miki, Jun
Kimura, Takahiro
Ohno, Yoshio
Azuma, Haruhito
Shiroki, Ryoichi
CLINICAL GENITOURINARY CANCER, 2024, 22 (01) : 76 - 83
[48] CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND CLINICAL OUTCOME IN METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH NIVOLUMAB: A REAL-WORLD MULTI-INSTITUTIONAL RETROSPECTIVE STUDY
Kato, Taigo
Nagahara, Akira
Kawamura, Norihiko
Nakata, Wataru
Soda, Tetsuji
Matsuzaki, Kyosuke
Hatano, Koji
Kawashima, Atsunari
Ujike, Takeshi
Nishimura, Kensaku
Takada, Shingo
Tsujihata, Masao
Yamaguchi, Seiji
Takao, Tetsuya
Nishimura, Kazuo
Uemura, Motohide
Nonomura, Norio
JOURNAL OF UROLOGY, 2021, 206 : E258 - E258
[49] Safety and efficacy outcomes in immune checkpoint inhibitor (ICI)-treated metastatic urothelial carcinoma (mUC) patients (pts) requiring treatment interruption (TI) due to immune-related adverse events (irAEs).
Nizam, Amanda
Sheng, Iris Yeong-Fung
Allman, Kimberly D.
Martin, Allison
Gilligan, Timothy D.
Gupta, Shilpa
Ornstein, Moshe Chaim
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[50] Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are predictors of immune-related adverse events during nivolumab monotherapy for metastatic renal cell carcinoma
Iemura, Y.
Miyake, M.
Fujimoto, K.
ANNALS OF ONCOLOGY, 2024, 35 : S1521 - S1522

← 1 2 3 4 5 →